[1] 姚东亚,罗源,盛光耀,等.儿童HB36例预后分析.临床儿科杂志,2017,35(2):121-124.
[2] De Ioris M,Brugieres L,Zimmermann A,et al.Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis:the SIOPEL group experience. Eur J Cancer,2008,44(4):545-550.
[3] D'Antiga L,Vallortigara F,Cillo U,et al. Features predicting unresectability in hepatoblastoma. Cancer,2007,110(5):1050-1058.
[4] van Dalen EC,Rapha l MF,Caron HN,et al. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev,2014,9:CD006647.
[5] Tannuri AC,Cristofani LM,Teixeira RA,et al.New concepts and outcomes for children with hepatoblastoma based on the experience of a tertiary center over the last 21 years. Clinics (So Paulo,Brazil),2015,70(6):387-392.
[6] Zhang YT,Feng LH,Zhong XD,et al.Vincristine and irinotecan in children with relapsed hepatoblastoma:a single-institution experience. Pediat Hematol Oncol,2015,32(1):18-25.
[7] Becker K,Furch C,Schmid I,et al.Impact of postoperative complications on overall survival of patients with hepatoblastoma. Pediat Blood Cancer,2015,62(1):24-28. |
